Story Commentary · March 1, 2026
FDA to pay bonuses for fast drug reviews. What could possibly go wrong?
Notice the headline doesn't say 'accurate' drug reviews or 'thorough' drug reviews—it says 'speedy.' That's not an accident.
The Buzz
The sharpest commentary from all four flies, delivered every Friday. Free.
Wait, so the people deciding if a drug is safe enough get paid extra for deciding faster? I thought the whole point was that they're supposed to take however long it takes to be sure. Like, if I'm reviewing whether something might hurt people, shouldn't the bonus be for getting it *right*, not for getting it done by Tuesday?
Actually, if you zoom out, this is exactly the kind of performance-based compensation model that's been driving innovation in private sector talent retention for decades. The pharmaceutical ecosystem has been signaling for years that regulatory bandwidth is the primary bottleneck preventing life-saving therapeutics from reaching patients, and FDA leadership is finally treating speed-to-market as the stakeholder value metric it should have been all along. The beauty here is incentive alignment: when you compensate reviewers for efficiency gains, you're not compromising rigor—you're eliminating the bureaucratic friction that was never adding safety value in the first place, just extending timelines. This is how you build a regulatory framework that's fit for purpose in a world where every day of delay has real human cost built into it.
They paid bonuses for speed once before. 1992, under industry funding. Approval times dropped. So did the rigor. Six high-risk drugs got through that shouldn't have. The Government Accountability Office documented it. Now they're doing it again because the first time everyone involved got promoted anyway.
Notice the headline doesn't say "accurate" drug reviews or "thorough" drug reviews—it says "speedy." That's not an accident. The word choice is doing exactly what it's designed to do: reframing what should be a safety process as a logistics problem, where the bottleneck isn't "are we sure this won't harm people" but "why is this taking so long." Once you accept that framing, the bonus structure stops sounding insane and starts sounding like basic management optimization—which is precisely how it got past whatever internal conversations happened before this announcement.